Galapagos to Present at 37th Annual J.P. Morgan Healthcare Conference

Mechelen, Belgium; 21 December 2018, 22.01 CET - Galapagos NV (((Euronext &, NASDAQ:GLPG) will participate in the 37th Annual J.P. Morgan Healthcare Conference on January 8 & 9, 2019.

Onno van de Stolpe, CEO, will present on Wednesday, January 9 at 20:30 CET (11:30 a.m. Pacific time). The presentation will be live audio webcast and can be accessed via the following link: https://jpmorgan.metameetings.net/events/healthcare19/sessions/23994-galapagos-nv/webcast. A replay of the webcast will be available for 90 days on the Galapagos' website at www.glpg.com.

About Galapagos

Galapagos (((Euronext &, NASDAQ:GLPG) discovers and develops small molecule medicines with novel modes of action, three of which show promising patient results and are currently in late-stage development in multiple diseases. Our pipeline comprises Phase 3 through to discovery programs in inflammation, fibrosis, osteoarthritis and other indications. Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. More information at glpg www.glpg.com.

Investors:

Elizabeth Goodwin

VP IR & Corporate Communications

+1 781 460 1784

 

Sofie Van Gijsel

Director IR

+32 485 19 14 15

ir@glpg.com

 

Media:

Evelyn Fox

Director Communications

+31 6 53 591 999

communications@glpg.com



Forward-looking statements

This release may contain forward-looking statements. Such forward-looking statements are not guarantees of future results. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any forward-looking statements in this document, unless specifically required by law or regulation.

Attachment

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!